|
Terazosin drug manufactured under the brand name Hytrin is used for
treatment of enlarged prostate and several other bladder related
diseases. Food and Drug Administration of United states have
certified Parenteal Company for the development of other generic
components. This oral treatment for enlarged prostate was thus
approved by the United States (US) Food and drug Administration as
Takeda Pharmaceuticals American. In 2000 the FDA had received 217
spontaneous reports through the MedWatch system through the prostate
patients.
The FDA has made strict specific laws for the drugs only to be
supplied to doctors. FDA also suggests the use of drugs only to
patients suffering from enlarged prostate. In July 2000 American
Association noticed that this drug was given even to patients
suffering from heart problems and so a requirement to keep a check
on its prescription was needed. Thus in July 2001 FDA included some
warning sections with the Hytrin. Terazosin pills and solutions are
clearly specified by its manufacturer regarding its use, expiry,
application etc.
This product is saled under the brand “Hytrin” by the Parenteal
Company. The approval of Terazosin was based on a review of clinical
trails and studies by double-blind, placebo controlled department,
which was the data from US health departments. FDA has specifically
given the dosage form s and contents that the drug should carry.
Terazosin solution should carry only 15mg/40ml while Terazosin
tablets can contain 5mg, 10mg, 35mg, 40mg, 70mg. The Federal
Government has given the right for Parenteal Company to conduct
future tests on developing prostate drugs.
|
